-
Innovation Ranking
NewInnovation Ranking – Cyclacel Pharmaceuticals Inc
Cyclacel Pharmaceuticals Inc (Cyclacel) is a biopharmaceutical company that develops oral therapies. The company develops small molecule drugs that target various phases of cell cycle control for the treatment of cancer and other serious diseases. Its products include sapacitabine, seliciclib, PLK inhibitor and CDK inhibitor. Cyclacel’s sapacitabine is the drug candidate used to treat the patients with acute myeloid leukemia. The company’s seliciclib is an orally available, cyclin dependent kinase inhibitor. It offers products for the treatment of anti-infective, autoimmune,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – VCAR33 (Autologous) in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - VCAR33 (Autologous) in Refractory Acute Myeloid Leukemia report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. VCAR33 (Autologous) in Refractory Acute Myeloid Leukemia Drug Details:...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SynKIR-110 in Bile Duct Cancer (Cholangiocarcinoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SynKIR-110 in Bile Duct Cancer (Cholangiocarcinoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SynKIR-110 in Bile Duct Cancer (Cholangiocarcinoma) Drug Details: SynKIR-110 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TransCon IL-2 Beta/Gamma in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TransCon IL-2 Beta/Gamma in Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TransCon IL-2 Beta/Gamma in Melanoma Drug Details: Recombinant Protein is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Bevacizumab in Nasopharyngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bevacizumab in Nasopharyngeal Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bevacizumab in Nasopharyngeal Cancer Drug Details: Bevacizumab (Avastin) is a recombinant humanized...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AMG-305 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AMG-305 in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AMG-305 in Pancreatic Cancer Drug Details: Monoclonal antibody is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fadraciclib in Ovarian Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fadraciclib in Ovarian Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fadraciclib in Ovarian Cancer Drug Details: CYC-065 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fadraciclib in Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fadraciclib in Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fadraciclib in Chronic Lymphocytic Leukemia (CLL) Drug Details: CYC-065...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Fadraciclib in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fadraciclib in Myelodysplastic Syndrome report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fadraciclib in Myelodysplastic Syndrome Drug Details: CYC-065 is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Fadraciclib in Metastatic Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Fadraciclib in Metastatic Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Fadraciclib in Metastatic Breast Cancer Drug Details: CYC-065 is under development...